1h Free Analyst Time
The proton pump inhibitors (PPIs) market is forecasted to grow by USD 819.5 million during 2024-2029, accelerating at a CAGR of 4.7% during the forecast period. The report on the proton pump inhibitors (PPIs) market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by reformulation of drugs, growth in prescription rate, and strong prevalence of gastroesophageal reflux disease.
The proton pump inhibitors (PPIs) market is segmented as below:
By Product
- OTC PPIs
- Prescription PPIs
By Route Of Administration
- Oral
- Injectable
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the proton pump inhibitors (PPIs) market covers the following areas:
- Proton Pump Inhibitors (PPIs) Market sizing
- Proton Pump Inhibitors (PPIs) Market forecast
- Proton Pump Inhibitors (PPIs) Market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Product
9 Market Segmentation by Route of Administration
10 Customer Landscape
11 Geographic Landscape
12 Drivers, Challenges, and Opportunity/Restraints
13 Competitive Landscape
14 Competitive Analysis
15 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global proton pump inhibitors (PPIs) market: Amgen Inc., AstraZeneca Plc, Aurobindo Pharma Ltd., Bausch Health Companies Inc., Bayer AG, Cipla Inc., Dr Reddys Laboratories Ltd., Eisai Co. Ltd., Eli Lilly and Co., Glenmark Pharmaceuticals Ltd., Johnson and Johnson Inc., Perrigo Co. Plc, Pfizer Inc., RedHill Biopharma Ltd., Sanofi SA, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., The Procter and Gamble Co., and Zydus Lifesciences Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is growing geriatric population."
According to the report, one of the major drivers for this market is the reformulation of drugs.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen Inc.
- AstraZeneca Plc
- Aurobindo Pharma Ltd.
- Bausch Health Companies Inc.
- Bayer AG
- Cipla Inc.
- Dr Reddys Laboratories Ltd.
- Eisai Co. Ltd.
- Eli Lilly and Co.
- Glenmark Pharmaceuticals Ltd.
- Johnson and Johnson Inc.
- Perrigo Co. Plc
- Pfizer Inc.
- RedHill Biopharma Ltd.
- Sanofi SA
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Co. Ltd.
- Teva Pharmaceutical Industries Ltd.
- The Procter and Gamble Co.
- Zydus Lifesciences Ltd.
